Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation
Top Cited Papers
- 18 January 2004
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 31 (1) , 11-19
- https://doi.org/10.1016/j.nucmedbio.2003.07.003
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo αvβ3 integrin related tumor imagingNuclear Medicine and Biology, 2003
- In Vitro and in Vivo Evaluation of a Technetium-99m-Labeled Cyclic RGD Peptide as a Specific Marker of αVβ3 Integrin for Tumor ImagingBioconjugate Chemistry, 2002
- Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp LigandScience, 2002
- Crystal Structure of the Extracellular Segment of Integrin αVβ3Science, 2001
- Peptide and protein PEGylation: a review of problems and solutionsPublished by Elsevier ,2001
- Mediators of Angiogenesis: The Role of Cellular Adhesion Molecules.Trends in Glycoscience and Glycotechnology, 1999
- Clinical Applications of Research on AngiogenesisNew England Journal of Medicine, 1995
- Requirement of Vascular Integrin α v β 3 for AngiogenesisScience, 1994
- Extracellular matrix and cell shape: Potential control points for inhibition of angiogenesisJournal of Cellular Biochemistry, 1991
- Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors.The Journal of cell biology, 1988